Sökning: id:"swepub:oai:DiVA.org:uu-103268" >
Pharmacokinetics of...
Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia
-
- Lönnerholm, Gudmar (författare)
- Uppsala universitet,Institutionen för kvinnors och barns hälsa,Barnonkologisk forskning/Pfeifer
-
Valsecchi, Maria Grazia (författare)
-
De Lorenzo, Paola (författare)
-
visa fler...
-
Schrappe, Martin (författare)
-
Hovi, Liisa (författare)
-
Campbell, Myriam (författare)
-
Mann, Georg (författare)
-
Janka-Schaub, Gritta (författare)
-
Li, Chi-Kong (författare)
-
Stary, Jan (författare)
-
Hann, Ian (författare)
-
Pieters, Rob (författare)
-
visa färre...
-
(creator_code:org_t)
- Wiley, 2009
- 2009
- Engelska.
-
Ingår i: Pediatric Blood & Cancer. - : Wiley. - 1545-5009 .- 1545-5017. ; 52:5, s. 596-601
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: Interfant-99 was an international collaborative treatment protocol for infants with acute lymphoblastic leukemia (ALL). PROCEDURE: We collected data on 103 infants at the time of their first treatment with high-dose methotrexate (HD MTX), 5 g/m(2). Children <6 months of age received two-third of the calculated dose based on body surface area (BSA), children 6-12 months three-fourth of the calculated dose, and children >12 months full dose. RESULTS: The median steady-state MTX concentration at the end of the 24-hr infusion was 57.8 microM (range 9.5-313). The median systemic clearance was 6.22 L/hr/m(2) BSA, and tended to increase with age (P = 0.099). Boys had higher clearance than girls, 6.77 and 5.28 L/hr/m(2) (P = 0.030), and tended to have lower median MTX concentration at 24 hr. Eight infants had MTX levels below 20 microM, a level judged to be sufficient in B-lineage ALL in children >1 year of age. All infants tolerated the dose well enough to receive a second dose of HD MTX without dose reduction. We found no significant effect on disease-free survival for MTX steady-state concentration, MTX clearance, or time to MTX below 0.2 microM. CONCLUSIONS: Our data provide no support for a change in the dosing rules for MTX used in Interfant-99. However, in view of the poor treatment results for infants, one might consider increase in the dose for patients who reach plasma levels below median after the first MTX dose.
Nyckelord
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Lönnerholm, Gudm ...
-
Valsecchi, Maria ...
-
De Lorenzo, Paol ...
-
Schrappe, Martin
-
Hovi, Liisa
-
Campbell, Myriam
-
visa fler...
-
Mann, Georg
-
Janka-Schaub, Gr ...
-
Li, Chi-Kong
-
Stary, Jan
-
Hann, Ian
-
Pieters, Rob
-
visa färre...
- Artiklar i publikationen
-
Pediatric Blood ...
- Av lärosätet
-
Uppsala universitet